Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Jeffrey Demanes

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Brachytherapy|August 3, 2014
High-dose-rate brachytherapy as monotherapy for prostate cancerD Jeffrey Demanes, Michel I Ghilezan
Brachytherapy|January 25, 2021
Brachytherapy of the head and neck: An University of California Los Angeles guide to morbidity reductionPuja Venkat, James Han, D Jeffrey Demanes
Brachytherapy|June 15, 2014
A critical ACR appropriateness Criteria omissionLeland Rogers, John Hayes, D Jeffrey Demanes
American Journal of Clinical Oncology|April 29, 2009
Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivationD Jeffrey Demanes, David Brandt, Lionel Schour, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year resultsD Jeffrey Demanes, Rodney R Rodriguez, Lionel Schour, et al.
Medical Physics|July 3, 2016
Comment on "Medical use of all high activity sources should be eliminated for security concerns" [Med. Phys. 42, 6773-6775 (2015)]J Daniel Pennington, Sang-June Park, Percy P Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Brachytherapy: Where Has It Gone…Again?Shyamal Patel, Omar Ragab, D Jeffrey Demanes, et al.
Brachytherapy|December 25, 2014
A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapyShane Mesko, Sang-June Park, Amar U Kishan, et al.
Prostate Cancer|November 14, 2013
Quantifying the ki-67 heterogeneity profile in prostate cancerShane Mesko, Patrick Kupelian, D Jeffrey Demanes, et al.
Brachytherapy|January 23, 2017
The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of radionuclide-based high-dose-rate brachytherapyBeth A Erickson, Nathan H J Bittner, Manjeet Chadha, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Brachytherapy|August 3, 2014
High-dose-rate brachytherapy as monotherapy for prostate cancerD Jeffrey Demanes, Michel I Ghilezan
Brachytherapy|January 25, 2021
Brachytherapy of the head and neck: An University of California Los Angeles guide to morbidity reductionPuja Venkat, James Han, D Jeffrey Demanes
Brachytherapy|June 15, 2014
A critical ACR appropriateness Criteria omissionLeland Rogers, John Hayes, D Jeffrey Demanes
American Journal of Clinical Oncology|April 29, 2009
Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivationD Jeffrey Demanes, David Brandt, Lionel Schour, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year resultsD Jeffrey Demanes, Rodney R Rodriguez, Lionel Schour, et al.
Medical Physics|July 3, 2016
Comment on "Medical use of all high activity sources should be eliminated for security concerns" [Med. Phys. 42, 6773-6775 (2015)]J Daniel Pennington, Sang-June Park, Percy P Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Brachytherapy: Where Has It Gone…Again?Shyamal Patel, Omar Ragab, D Jeffrey Demanes, et al.
Brachytherapy|December 25, 2014
A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapyShane Mesko, Sang-June Park, Amar U Kishan, et al.
Prostate Cancer|November 14, 2013
Quantifying the ki-67 heterogeneity profile in prostate cancerShane Mesko, Patrick Kupelian, D Jeffrey Demanes, et al.
Brachytherapy|January 23, 2017
The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of radionuclide-based high-dose-rate brachytherapyBeth A Erickson, Nathan H J Bittner, Manjeet Chadha, et al.
Pageof 7